首页 | 本学科首页   官方微博 | 高级检索  
     


Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin
Authors:Ryan D. Cassaday  David I. Marks  Daniel J. DeAngelo  Elias J. Jabbour  Anjali S. Advani  Susan O’Brien  Tao Wang  Alexander Neuhof  Erik Vandendries  Hagop M. Kantarjian  Wendy Stock  Matthias Stelljes
Affiliation:1. University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA, USA;2. University Hospitals Bristol, Bristol, UK;3. Dana-Farber Cancer Institute, Boston, MA, USA;4. University of Texas MD Anderson Cancer Center, Houston, TX, USA;5. Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA;6. Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA, USA;7. Pfizer Inc, Cambridge, MA, USA;8. Pfizer Pharma GmbH, Berlin, Germany;9. University of Chicago, Chicago, IL, USA;10. Universitätsklinikum Münster, Münster, Germany
Abstract:
Keywords:acute lymphoblastic leukaemia  inotuzumab ozogamicin  relapsed  treatment cycles  HSCT
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号